The American biotechnology company Novavax announced the new protein vaccine of NVX-CoV2373 two doses against coronavirus had an efficacy of 80% against Covid-19according to the results of the final phase of its test in adolescents 12 to 17 years old.
The test was performed on 2,247 adolescents between May and September 2021, when the Delta variant was still predominant, against which the vaccine in particular was 82% effective. The company plans to submit, within the first quarter of this year, an application for approval of the use of its vaccine to adolescents. Last month, it submitted a similar application to the United States for the use of its vaccine in adults, after testing it on about 30,000 people, where it showed an effectiveness of 90.4%.
The vaccine, according to Reuters, has already been approved by the European Union and the World Health Organization, as well as Britain and New Zealand. Novavax said that in its test in adolescents the vaccine was well tolerated and there were no cases of myocarditis. The company also assured that it continues to monitor for other possible side effects, as its vaccine is gradually being used more widely by the general population internationally.
Follow Skai.gr on Google News
and be the first to know all the news
